CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2017 World Congress of Melanoma
Oncology Conference Multimedia
View more videos >>
Dr. Amaria on Genetically Modified TILs in Melanoma
Dr. Schadendorf on the Efficacy of Targeted Therapy Plus Checkpoint Inhibitors
Dr. Postow on BRAF and MEK Inhibitor Combination Studies in Melanoma
Oncology Conference Articles
Glembatumumab Vedotin Induces 61% DCR in Uveal Melanoma
Glembatumumab vedotin (CDX-011) induced a disease control rate of 61% in patients with metastatic uveal melanoma, despite a low a low objective response rate of 6%.
Adjuvant Nivolumab/Ipilimumab Sustains RFS Benefit in Melanoma at 3 Years
The combination of adjuvant nivolumab and ipilimumab led to a 3-year relapse-free survival rate of 71% in patients with high-risk resected stage IIIC/IV melanoma.
Adjuvant Dabrafenib/Trametinib RFS Benefit Persists Across Melanoma Subgroups
A doubling in 3-year relapse-free survival rates remained consistent across patient subgroups treated with dabrafenib and trametinib, when compared with placebo, for patients with
-mutant stage III melanoma.
Nivolumab/Ipilimumab Combo Active for Melanoma Brain Mets
The combination of nivolumab and ipilimumab showed an intracranial response rate of 46% for asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.
Immune-Stimulator Boosts Pembrolizumab in Melanoma Patients With "Cold" Tumors
Adding the immune stimulator ImmunoPulse IL-12 to pembrolizumab (Keytruda) produced promising activity among patients with melanoma identified as unlikely responders to anti–PD-1 therapies.
Triplet Therapy on Horizon for BRAF+ Melanoma
The combination of anti–PD-1/PD-L1 immunotherapy with BRAF plus MEK inhibitors is advancing rapidly following early promising phase results for patients with
-mutant advanced melanoma.
Novel Combinations Mark Next Step for Melanoma
Immunotherapy has led a transformation for melanoma care but combinations of anti–PD-1 and CTLA-4 agents are toxic and biomarkers are not available to help personalized treatment, calling for further research into less toxic and more effective options.
Early Study Shows Promise for Genetically Modified TILs in Advanced Melanoma
Treatment with genetically engineered tumor infiltrating lymphocytes showed some signs of activity and very little added toxicity for patients with metastatic melanoma.
Immunotherapy Infuses New Hope Into Merkel Cell Carcinoma Care
While chemotherapy has historically been used to treat patients with Merkel cell carcinoma, immunotherapy advances have infused new hope into the treatment landscape.
Intralesional Combinations Pave the Way for Melanoma Treatment
The use of intralesional therapies in combination with checkpoint inhibitors has shown to be an improvement to monotherapy and combinations with immunotherapy in melanoma.
FDA Approvals in Breast Cancer and Prostate Cancer, Priority Review in Breast Cancer, and More
FDA Approves Ivosidenib for IDH1+ AML
Dr. Razis on Molecular Targeting of Glioblastoma
Immunotherapy Treatment Options Continue to Grow in Relapsed/Refractory Multiple Myeloma
PIK3CA Remains Elusive in Breast Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.